Allogene Therapeutics Cash Flow Statement (2018-2026) | ALLO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Operating Activities
Net Income (Quarter)	-160.39M	3.07M	-81.52M	-109.12M	-224.93M	-100.54M	-100.03M	-113.00M	-91.53M	-72.84M	-77.68M	-191.98M	-78.68M	-57.54M	-73.75M	-76.28M	-65.29M	-50.88M	-145.21M	-141.67M
Depreciation and Depletion (Quarter)	2.33M	4.24M	3.69M	3.67M	3.86M	3.07M	3.51M	3.64M	3.57M	3.48M	3.56M
Share-based Compensation (Quarter)	58.78M	22.04M	22.32M	22.89M	21.15M	-34.99M	18.77M	16.59M	-35.36M		2.41M		36.46M	12.87M	12.18M	-12.18M			8.27M	12.44M
Deferred Taxes (Quarter)
Asset Writedowns and Impairment (Quarter)										6.50M		5.00M	10.73M			2.38M		0.02M
Cash from Operations (Quarter)	-48.88M	-45.44M	-68.24M	-42.53M	-47.66M	-62.10M	-66.64M	-61.86M	-55.53M	-53.71M	-55.90M	-63.59M	-44.12M	-36.70M	-52.93M	-39.03M	-29.69M	-27.60M	-12.91M	-32.00M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter)	2.33M	4.24M	3.69M	3.67M	3.86M	3.07M	3.51M	3.64M	3.57M	3.48M	3.56M	3.64M	3.21M	3.23M	3.10M	3.11M	3.10M	3.10M	2.87M	2.65M
Change in Working Capital
Change in Account Payables (Quarter)	0.19M	-2.04M	-0.51M	1.42M	1.01M	2.94M	1.06M	-4.29M	-3.97M	-0.30M	-0.12M	6.81M	-7.23M	0.03M	-0.34M	-0.42M	-1.07M	0.60M	0.66M	1.03M
Change in Accured Expenses (Quarter)	8.89M	-2.77M	-9.05M	5.71M	1.95M	3.14M	5.69M	-0.08M	-12.72M	0.29M	-5.69M	-0.98M	2.53M	2.88M	-5.22M	1.74M	1.09M	-0.12M	-5.10M	2.28M
Other Working Capital Changes (Quarter)	40.78M	-1.18M	-0.60M	-0.43M	1.01M	-0.00M	-0.00M	-0.62M	0.01M	-5.39M	0.01M	0.04M	-4.58M	-1.78M	-1.83M	-1.93M	-1.85M	6.75M	0.32M	-2.04M
Investing Activities
Capital Expenditures (Quarter)	-0.71M	-0.34M	1.90M	0.90M	0.41M	1.98M	1.03M	-0.98M	1.28M	0.12M	-1.45M	1.45M	0.44M	-4.72M		0.21M	0.97M	0.10M	0.01M	0.01M
Change in Acquisitions & Divestments (Quarter)	161.78M	-645.85M		185.80M	-185.80M	359.46M	5.62M		455.84M	136.34M	103.27M	117.22M	-215.09M		56.50M	53.80M	-110.30M		72.11M	36.31M
Cash from Investing Activities (Quarter)	13.01M	29.25M	-22.38M	54.03M	24.91M	49.60M	112.94M	17.16M	-34.27M	67.46M	22.13M	74.61M	-75.99M	54.93M	6.18M	43.84M	11.94M	33.61M	-29.59M	-147.56M
Financing Activities
Other financing activities (Quarter)	-3.66M		1.53M	-1.22M	2.15M	-1.97M				2.09M		0.86M	0.68M	2.30M		0.64M	6.27M		0.45M
Debt Issuance and Repayment
Long-Term Debt Issuances (Quarter)
Change in Capital Stock
Shares Issued (Quarter)
Net Equity Issued and Repurchased (Quarter)										91.11M		105.28M	-104.26M	5.74M	10.00M	1.51M	-11.52M		20.67M	167.20M
Misc.
Cash from Financing Activities (Quarter)	2.38M	0.32M	1.81M	0.02M	1.07M	0.05M	1.73M	89.52M	4.29M	0.15M	1.65M	108.60M	0.68M	5.74M	13.99M	5.07M	3.24M	7.86M	21.12M	187.87M
Change in Cash (Quarter)	-33.48M	-15.86M	-88.80M	11.53M	-21.68M	-12.45M	48.03M	44.83M	-85.51M	13.91M	-32.12M	119.63M	-119.43M	23.98M	-32.76M	9.88M	-14.52M	13.87M	-21.38M	8.32M
Free Cash Flow (Quarter)	-48.16M	-45.09M	-70.14M	-43.43M	-48.06M	-64.08M	-67.67M	-60.88M	-56.81M	-53.83M	-54.45M	-65.03M	-44.55M	-31.98M	-52.93M	-39.24M	-30.66M	-27.70M	-12.92M	-32.01M
Net Cash Flow (Quarter)	-33.48M	-15.86M	-88.80M	11.53M	-21.68M	-12.45M	48.03M	44.83M	-85.51M	13.91M	-32.12M	119.63M	-119.43M	23.98M	-32.76M	9.88M	-14.52M	13.87M	-21.38M	8.32M

Research Tools

Datasets

Plans

Developers

Allogene Therapeutics Cash Flow Statement (2018-2026) | ALLO

Research Tools

Datasets

Plans

Developers

Allogene Therapeutics Cash Flow Statement (2018-2026) | ALLO

Create an account

Sign In

Reset Password